Cargando…
What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study
This paper addresses the SARS-CoV-2 vaccination progress in Australia. Globally, Australia was initially praised for its national COVID-19 response, reflecting well with regard to case numbers and mortality rates. However, Australia’s progress with its vaccine rollout has come under scrutiny. When c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620945/ https://www.ncbi.nlm.nih.gov/pubmed/36417218 http://dx.doi.org/10.3390/epidemiologia2040040 |
_version_ | 1784821431103651840 |
---|---|
author | Choiseul, Juliette Caroline Emmerson, Paris Jade Eslanloo Pereira, Turan Hosseinalipour, Seyed-Moeen Hasselgård-Rowe, Jennifer |
author_facet | Choiseul, Juliette Caroline Emmerson, Paris Jade Eslanloo Pereira, Turan Hosseinalipour, Seyed-Moeen Hasselgård-Rowe, Jennifer |
author_sort | Choiseul, Juliette Caroline |
collection | PubMed |
description | This paper addresses the SARS-CoV-2 vaccination progress in Australia. Globally, Australia was initially praised for its national COVID-19 response, reflecting well with regard to case numbers and mortality rates. However, Australia’s progress with its vaccine rollout has come under scrutiny. When compared globally, it fares very low in terms of the number of vaccine doses administered. This paper discusses the first three months of the vaccination process, and the challenges Australia faced during that time. Through an extensive literature review, data was collected on relevant topics concerning all aspects of the Australian COVID-19 situation. The following key points are discussed: the specific COVID-19 organisation at the federal vs. the state government levels, the Australian economy, the vaccine supply strategy, and the vaccine priority roll out. In conclusion, we highlight the impact of Australia initially relying heavily on the AstraZeneca vaccine, which subsequently came under fire regarding safety issues likely linking the vaccine to thrombosis with thrombocytopenia syndrome (TTS). |
format | Online Article Text |
id | pubmed-9620945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96209452022-11-18 What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study Choiseul, Juliette Caroline Emmerson, Paris Jade Eslanloo Pereira, Turan Hosseinalipour, Seyed-Moeen Hasselgård-Rowe, Jennifer Epidemiologia (Basel) Case Report This paper addresses the SARS-CoV-2 vaccination progress in Australia. Globally, Australia was initially praised for its national COVID-19 response, reflecting well with regard to case numbers and mortality rates. However, Australia’s progress with its vaccine rollout has come under scrutiny. When compared globally, it fares very low in terms of the number of vaccine doses administered. This paper discusses the first three months of the vaccination process, and the challenges Australia faced during that time. Through an extensive literature review, data was collected on relevant topics concerning all aspects of the Australian COVID-19 situation. The following key points are discussed: the specific COVID-19 organisation at the federal vs. the state government levels, the Australian economy, the vaccine supply strategy, and the vaccine priority roll out. In conclusion, we highlight the impact of Australia initially relying heavily on the AstraZeneca vaccine, which subsequently came under fire regarding safety issues likely linking the vaccine to thrombosis with thrombocytopenia syndrome (TTS). MDPI 2021-12-03 /pmc/articles/PMC9620945/ /pubmed/36417218 http://dx.doi.org/10.3390/epidemiologia2040040 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Choiseul, Juliette Caroline Emmerson, Paris Jade Eslanloo Pereira, Turan Hosseinalipour, Seyed-Moeen Hasselgård-Rowe, Jennifer What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study |
title | What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study |
title_full | What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study |
title_fullStr | What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study |
title_full_unstemmed | What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study |
title_short | What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study |
title_sort | what can be learned from the early stages of the covid-19 vaccination rollout in australia: a case study |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620945/ https://www.ncbi.nlm.nih.gov/pubmed/36417218 http://dx.doi.org/10.3390/epidemiologia2040040 |
work_keys_str_mv | AT choiseuljuliettecaroline whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy AT emmersonparisjade whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy AT eslanloopereiraturan whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy AT hosseinalipourseyedmoeen whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy AT hasselgardrowejennifer whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy |